ClinicalTrials.gg
Active, not recruitingNCT04797403IMPACTS-MINDUpdated Oct 1, 2026

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control in Minimize Cognitive Decline

An interventional study of Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm in Hypertension and Cognitive Decline, sponsored by Tulane University. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Tulane University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Oct 2019, registered Mar 2021).
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,306
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Hypertension by Tulane University — 2 open to participants now, 7 under way, none of them phase 3. Hypertension · Tulane University.

Enrollment
6th of 15
1,306 · median 1,176
Started
2019
the only one that year
No phase
13 of 17
2 open now
Registered
10th of 17
by date

Among the 17 studies in Hypertension by Tulane University, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2019, is one of 13 with no phase, and was the 10th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 17 studies in Hypertension by Tulane University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypertension by Tulane University, or all of them as a file.
02

Study summary

The study will test a multifaceted strategy for implementing an intensive blood pressure intervention protocol targeting systolic BP \<120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in primary care. The proposed study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce blood pressure-related cognitive decline in low- income and minority populations. If proven effective, the implementation strategy for intensive blood pressure reduction could be adapted and scaled up in diverse primary care settings to prevent cognitive decline and clinical dementia.

Read the detailed description

African American and low-income populations bear a disproportionate burden of dementia and have been underrepresented in trials of cognitive impairment. The Systolic Blood Pressure Intervention Trial (SPRINT) showed that an intensive blood pressure (BP) intervention (target systolic BP \<120 mmHg) lowered the risk of cognitive impairment compared to a standard BP intervention (systolic BP target \<140 mmHg). The next important step is to determine how the successful SPRINT intensive blood pressure intervention can be implemented in a real-world clinic setting to prevent cognitive decline. The overall objective of the proposed study is to test a multifaceted strategy for implementing an intensive BP intervention protocol adapted from SPRINT targeting systolic BP \<120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in resource-constrained primary care practices in Louisiana and Mississippi. The RE-AIM (Reach Effectiveness Adoption Implementation Maintenance) framework has been used to guide the development and evaluation of the multifaceted implementation strategy, including protocol-based treatment that employs the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT findings, shared- decision making, team-based collaborative care, BP audit and feedback, home BP monitoring, and patient health coaching. Building on the ongoing Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS-BP) trial, the investigators will cost-effectively conduct a cluster- randomized trial in 40 primary care clinics that serve low-income populations in Louisiana and Mississippi. The primary outcome in the proposed trial is the net difference in mean change of global cognitive composite z-score from baseline to an average of 36 months between the intervention and enhanced usual care groups. Secondary outcomes include net difference in mean change of executive function and memory composite z-scores, systolic and diastolic BP, adverse effects, and quality of life. Implementation outcomes, including acceptability, adaptation, adoption, feasibility, fidelity, penetrance, and cost-effectiveness, will also be collected and used to improve intervention delivery during the trial. The proposed trial, with a sample size of 40 clinics (31.5 patients/clinic), has 93% statistical power to detect a 0.30 or higher difference in the global cognitive composite z-score at a 2-sided significance level of 0.05 assuming 20% loss to follow-up and an intra-cluster correlation of 0.05. In a meta-analysis of 5 clinical trials, the pooled effect size was 0.35 (95% CI 0.32, 0.38) for the global cognitive composite z-score. This study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce blood pressure-related cognitive decline in low-income and minority populations. If proven effective, the implementation strategy for intensive blood pressure reduction could be adapted and scaled up in diverse primary care settings to prevent cognitive decline and clinical dementia.

03

Conditions studied

  • Hypertension
  • Cognitive Decline
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Primary Care Clinics

  • Predominantly managing underserved populations with health disparities (ethnic minorities, low-income groups, and residents of rural areas and inner cities).
  • Having electronic medical record systems.
  • Serving >200 hypertension patients (ICD-10-CM I10-I15) during the previous year.
  • Not participating in other hypertension control programs
  • Not sharing providers or nurses/pharmacists with other participating clinics.

Inclusion Criteria for Study Participants

  • Men or women aged ≥40 years (2/3 of participants ≥60 years) who receive primary care from participating clinics.
  • Systolic BP ≥ 140 mmHg at two screening visits for those not taking antihypertensive medication or systolic BP ≥ 130 mmHg at two screening visits for those taking antihypertensive medications
  • Pregnant women, women planning to become pregnant in the near future, women of and not practicing , and persons who cannot give will be excluded.
  • No diagnosis of dementia at baseline
  • Baseline score ≥ 10.
  • No diagnosis of end-stage renal disease, defined as dialysis or transplantation
  • Speak English as first language
  • No plans to change to a primary healthcare provider outside of their clinic in the near future
  • No individuals unlikely to complete the study, such as those who plan to move out of the study area in the near future and temporary migrant and homeless people
  • No immediate family members are staff at their clinic
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,306 participants (actual)

Study arms

  • Experimental
    Intervention

    The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.

    Behavioral: Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm

  • No intervention
    Enhanced Usual Care

    Enhanced usual care will include an education session on the ACC/AHA hypertension guideline to providers and proper BP measurement to providers and staff at enhanced usual care clinics.Otherwise, no active intervention will take place, and all usual care clinics will follow their routine clinic practice.

Interventions

  • BehavioralStepped-care protocol adapted from the SPRINT intensive-treatment algorithm

    The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.

06

What researchers measure

Primary outcomes

  1. Net difference in mean change in cognitive decline

    The net difference in mean change of global cognitive composite z-score over an average 36 months between intervention and enhanced usual care groups

    Time frame: Baseline to an average of 36 months

Secondary outcomes

  1. Net difference in mean change in MoCA score

    Difference between the intervention and usual care group in mean change in Montreal Cognitive Assessment (MoCA) over an average 36 months.

    Time frame: Baseline to an average of 36 months

  2. Net difference in mean change in executive function

    Difference between the intervention and usual care group in mean change in executive function composite z-score (calculated from average of z-scores from individual tests: DSC, Trails A \& B, DST, Category Fluency) over an average 36 months.

    Time frame: Baseline to an average of 36 months

  3. Net difference in mean change in memory function

    Difference between the intervention and usual care group in mean change in memory composite z-score (calculated from average of z-scores from individual tests: MoCA immediate \& delayed word recall, HVLT-R immediate recall) over an average 36 months.

    Time frame: Baseline to an average of 36 months

  4. Net difference in mean change in systolic blood pressure

    Difference between the intervention and usual care group in mean change in systolic blood pressure over an average 36 months.

    Time frame: Baseline to an average of 36 months

  5. Net difference in mean change in diastolic blood pressure

    Difference between the intervention and usual care group in mean change in diastolic blood pressure over an average 36 months.

    Time frame: Baseline to an average of 36 months

Other outcomes

  1. Side effects

    Difference between the intervention and usual care group in frequency of side effects (collected via detailed questionnaire) over an average 36 months.

    Time frame: Baseline to an average of 36 months

  2. Health-related Quality of Life (HRQoL)

    Difference between the intervention and usual care group in mean change in health-related quality of life (measured using the 12-Item Short Form Survey) over an average 36 months.

    Time frame: Baseline to an average of 36 months

  3. Difference in proportion of patients with adjudicated mild cognitive impairment (MCI) or probable dementia (exploratory outcome)

    Difference in adjudicated MCI and probable dementia at the termination visit between the intervention and usual care group. Based on pre-defined MoCA cutpoints, suspected cases of dementia/MCI will be randomly assigned to two adjudicators, blinded to treatment assignment, with expertise in dementia for review. Data used in the adjudication will include all available cognitive test data, functional assessment, and additional data including demographic information and medical records.

    Time frame: Baseline to an average of 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Our study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. Data will be prepared by the Study Data Coordinating Center and sent to the study's NIA Program Official for review prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." In addition, the investigators will offer, through our public access website, opportunities for outside investigators to collaborate with us using complete study data. At the completion of the project, the investigators will make all intervention materials and procedure manuals available to the public according to the approved plan for making data and materials available to the scientific community, lay public, and the NIH.

Supporting information: Study protocol

Time frame: Study data, including data from baseline and follow-up visits, will be prepared for transmission to the NIH data repository no later than 3 years after the end of the final patient follow-up or 2 years after the main paper of the trial has been published, whichever comes first.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Oct 2026, 84 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 84 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 15, 2021
StartActual
Oct 22, 2019
Primary completionEst.
Oct 2026was Aug 2026
CompletionEst.
Oct 2026was Aug 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Oct 2026
Oct 1, 2026
Study completion
Aug 2026→Oct 2026
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Aug 2026→Oct 2026
    Study completion Aug 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04797403
Lead sponsor
Tulane University
Responsible party
Katherine T Mills (Assistant Professor, Tulane University) — Principal investigator
First posted
Mar 15, 2021
Start date
Oct 22, 2019
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

Katherine T Mills, PhD
principal investigator · Tulane University
Jiang He, MD, PhD
principal investigator · Tulane University
Jeff D Williamson, MD
principal investigator · Wake Forest University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion